Progress in Medicinal Chemistry [Hardcover]

The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a 'quality lead', where these 'quality leads' come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.

*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirectPreface
List of Contributors
Hit and Lead Identification: Efficient practices for drug discovery
DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Recent Progress Towards Nonpeptide Ligands for the Melanocortin-4 Receptor
Tuberculosis chemotherapy: recent developments and future perspectives
Subject Index
Author Index (Volumes 1-45)
Subject Index (Volumes 1-45)A highly valuable reference for medicinal chemists, biologists, doctors, and pharmacistsDr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.

From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portló?